Last reviewed · How we verify

Acanya Gel

Padagis LLC · Phase 3 active Small molecule

Acanya Gel is a Topical antibiotic combination Small molecule drug developed by Padagis LLC. It is currently in Phase 3 development for Acne vulgaris. Also known as: Reference product.

Acanya Gel combines clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial oxidizing agent) to reduce acne-causing bacteria and decrease sebum production.

Acanya Gel combines clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial oxidizing agent) to reduce acne-causing bacteria and decrease sebum production. Used for Acne vulgaris.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameAcanya Gel
Also known asReference product
SponsorPadagis LLC
Drug classTopical antibiotic combination
TargetCutibacterium acnes (bacterial protein synthesis inhibition); benzoyl peroxide acts as an oxidizing antimicrobial
ModalitySmall molecule
Therapeutic areaDermatology
PhasePhase 3

Mechanism of action

Clindamycin inhibits bacterial protein synthesis, killing Cutibacterium acnes and other acne-associated bacteria. Benzoyl peroxide generates reactive oxygen species that further reduce bacterial load and have keratolytic properties. Together, these agents address both the bacterial and inflammatory components of acne.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Acanya Gel

What is Acanya Gel?

Acanya Gel is a Topical antibiotic combination drug developed by Padagis LLC, indicated for Acne vulgaris.

How does Acanya Gel work?

Acanya Gel combines clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial oxidizing agent) to reduce acne-causing bacteria and decrease sebum production.

What is Acanya Gel used for?

Acanya Gel is indicated for Acne vulgaris.

Who makes Acanya Gel?

Acanya Gel is developed by Padagis LLC (see full Padagis LLC pipeline at /company/padagis-llc).

Is Acanya Gel also known as anything else?

Acanya Gel is also known as Reference product.

What drug class is Acanya Gel in?

Acanya Gel belongs to the Topical antibiotic combination class. See all Topical antibiotic combination drugs at /class/topical-antibiotic-combination.

What development phase is Acanya Gel in?

Acanya Gel is in Phase 3.

What are the side effects of Acanya Gel?

Common side effects of Acanya Gel include Erythema, Dryness, Peeling, Irritation at application site.

What does Acanya Gel target?

Acanya Gel targets Cutibacterium acnes (bacterial protein synthesis inhibition); benzoyl peroxide acts as an oxidizing antimicrobial and is a Topical antibiotic combination.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing